{"id":6680,"date":"2022-10-25T06:00:00","date_gmt":"2022-10-25T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/"},"modified":"2022-10-25T06:00:00","modified_gmt":"2022-10-25T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-september-2022","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Lansering av NEX-22 inom typ 2-diabetes och nya partnerprojekt med stor potential<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under tredje kvartalet 2022<\/strong><\/p>\n<ul>\n<li>Nanexa AB meddelade under kvartalet att bolaget startar produktprojektet NEX-22 som adresserar en mycket stor marknad. I NEX-22 kommer bolaget utveckla en l\u00e5ngtidsverkandeformulering av liraglutid med PharmaShell\u00ae, f\u00f6r behandling av typ 2-diabetes. NEX-22 blir bolagets tredje egna produktutvecklingsprojekt<\/li>\n<li>Nanexa meddelade under kvartalet att bolaget ut\u00f6kade sitt samarbetsavtal med Applied Materials, Inc. Detta sker genom ett till\u00e4ggsavtal som reglerar kommersiella fr\u00e5gor och banar v\u00e4g f\u00f6r potentiella framtida licensavtal med kunder inom l\u00e4kemedelsbranschen<\/li>\n<li>Nanexa erh\u00f6ll ut\u00f6kat GMP certifikat fr\u00e5n L\u00e4kemedelsverket f\u00f6r tillverkning av kliniskt pr\u00f6vningsmaterial f\u00f6r sin nybyggda pilotanl\u00e4ggning i Uppsala<\/li>\n<li>Under kvartalet tecknade Nanexa ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med option p\u00e5 licens med ett av de st\u00f6rsta globala l\u00e4kemedelsbolagen, f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system PharmaShell i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r lokal administrering<\/li>\n<li>Nanexa AB och Vitrivax, Inc. gav under kvartalet in en skrivelse till domstolen i Delaware d\u00e4r de beg\u00e4rde att Nanexas st\u00e4mning avseende patentintr\u00e5ng f\u00f6rklaras vilande i avvaktan p\u00e5 att parterna finaliserar villkoren f\u00f6r en f\u00f6rlikning som man i allt v\u00e4sentligt kommit \u00f6verens om.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>I oktober 2022 tecknade Nanexa ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med ett l\u00e4kemedelsbolag specialiserat inom \u00f6gonomr\u00e5det, f\u00f6r utv\u00e4rdering av Nanexas drug delivery-system PharmaShell i en dep\u00e5formulering av ett specifikt l\u00e4kemedel f\u00f6r intravitreal administrering.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 juli \u2013 30 september 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 1 531 (826) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -11 927 (-7 857) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -12 045 (-7 904) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,24 (-0,18) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -21 297 (91 203) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 45 608 (119 799) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 30 september 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 2 040 (1 704) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -40 112 (-22 776) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -40 639 (-22 912) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,80 (-0,75) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -60 052 (107 108) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 45 608 (119 799) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida via f\u00f6ljande l\u00e4nk, https:\/\/nanexa.com\/finansiella-rapporter\/.<\/p>\n<p><strong>Rapportkommentar 25 oktober kl 13:00<\/strong><br \/>En lives\u00e4nd Rapportkommentar h\u00e5lls via Infront Direkt Studios kl 13:00, d\u00e4r vd David Westberg och Director Business Development Otto Skolling svarar p\u00e5 fr\u00e5gor fr\u00e5n reporter och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>S\u00e4ndningen kan ses p\u00e5 denna l\u00e4nk <a href=\"https:\/\/www.youtube.com\/watch?v=T76wpbdAq8k\" target=\"_blank\" rel=\"nofollow noopener\">denna l\u00e4nk<\/a>.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2022-10-25 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/2e4062e8-2df3-4714-9205-34834268908c\/nanexa-delarsrapport-jan-sep-2022.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa Del\u00e5rsrapport Jan Sep 2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lansering av NEX-22 inom typ 2-diabetes och nya partnerprojekt med stor potential<\/p>\n","protected":false},"template":"","class_list":["post-6680","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q3_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Lansering av NEX-22 inom typ 2-diabetes och nya partnerprojekt med stor potential\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2022\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2022\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-10-25T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2022\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022 - Nanexa AB","og_description":"Lansering av NEX-22 inom typ 2-diabetes och nya partnerprojekt med stor potential","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-10-25T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2022"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}